Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

@article{Visco2017RituximabBA,
  title={Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.},
  author={Carlo Visco and Annalisa Chiappella and Luca Nassi and Caterina Patti and Simone Ferrero and Daniela Barbero and Andrea Evangelista and Michele Spina and Annalia Molinari and Luigi Rigacci and M Kendouci Tani and Alice Di Rocco and Graziella Pinotti and Alberto Fabbri and Renato Zambello and Silvia Finotto and Manuel Gotti and Angelo Michele Carella and Flavia Salvi and Stefano A Pileri and Marco Ladetto and Giovannino Ciccone and Gianluca Gaidano and Marco Ruggeri and Maurizio Martelli and Umberto Vitolo},
  journal={The Lancet. Haematology},
  year={2017},
  volume={4 1},
  pages={e15-e23}
}
BACKGROUND The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymphoma, but its use was restricted by high haematological toxicity. We aimed to assess the efficacy and safety of an R-BAC regimen with low-dose cytarabine (RBAC500). METHODS In this multicentre, phase 2 trial, we recruited previously untreated patients with an established histological diagnosis of mantle cell lymphoma from 29 Fondazione Italiana Linfomi centres in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 21 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Randomized trial of bendamustine–rituximab or R-CHOP/R-CVP in fi rst-line treatment of indolent NHL or MCL: the BRIGHT study

IW Flinn, R van der Jagt, BS Kahl
Blood • 2014

Similar Papers

Loading similar papers…